SMS-oncology is a proud sponsor of the TAT 2013 Congress
22 January 2013, Eric van der Putten
Targeted therapies, which include monoclonal antibodies and small molecule inhibitors, have significantly changed the treatment of cancer over the past decade. These drugs are now a component of therapy for many common malignancies. A current overview of targeted drug development can be found here.
A recent example of the new age in cancer therapy is blinatumomab which produced an exceptionally high complete hematological and molecular remission rates in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) as presented at the 54th American Society of Hematology (ASH) Annual Meeting. Blinatumomab is a bispecific T-cell engaging (BiTE) antibody that directs cytotoxic T-cells to CD19 expressing target cells.
SMS-oncology is very actively involved in several drug development programs with targeted agents and therefore we are proud to sponsor the 2013 TAT (Targeted Anticancer Therapies) meeting in Paris, March 4-6. The TAT Congress Series provides a forum for in-depth discussion of emerging targeted agents for the treatment of cancer. TAT meetings are the leading oncology phase I meetings in Europe and a must-attend for clinical investigators as well as research scientists and drug development professionals from pharma, biotech companies and CROs.
TAT 2013 will feature a special event focusing on business-to-academia partnering and networking for biotech companies. Biotech companies will have the opportunity to interact closely with leading oncology phase I investigators and to showcase their innovations in oncology to the cancer research and development community.
At SMS-oncology we value face-to-face interactions in order to develop strong working relationships. Meetings like the Oncology Biotech Event at the TAT 2013 provide an excellent opportunity to get in contact with innovative oncology biotech companies. Furthermore we can enjoy new insights about targeted cancer therapeutics, especially those in the late preclinical and early clinical development stages.
We look forward meeting you at the TAT 2013 in Paris to discuss the importance of the latest innovative anticancer therapies and the early stage clinical trial space.